SEC Form 4 · accession 0001144204-17-012195
KIORA PHARMACEUTICALS INC · KPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Morton Goldberg
Director
Period of report
Feb 27, 2017
Accepted (ET)
Mar 1, 2017 · 5:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001372514
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 27, 2017 | M | 1,083 | $1.70 | A | 18,360 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.70 | Feb 27, 2017 | M | 1,083 | D | — | Jan 25, 2026 | Common Stock | 1,083 | 1,917 | D |
Explanation of responses
- F1The reporting person was granted an option to purchase these shares pursuant to the Issuer's 2014 Equity Incentive Plan. The option became exercisable as to 33% of the shares underlying the option on January 25, 2017, with 2.78% of the shares underlying the option vesting monthly thereafter.